Balyasny Asset Management
TNGX icon

Balyasny Asset Management’s Tango Therapeutics TNGX Stock Holding History

Balyasny Asset Management’s Portfolio TNGX Stock Details TNGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$63M Sell
2,016,379
-1,810,280
-47% -$44.8M 0.08% 299
2026
Q1 		$80.1M Sell
3,826,659
-1,451,921
-28% -$20.2M 0.1% 213
2025
Q4 		$46.8M Buy
5,278,580
+1,806,373
+52% +$15.6M 0.06% 376
2025
Q3 		$29.2M Buy
3,472,207
+224,744
+7% +$1.52M 0.04% 557
2025
Q2 		$16.6M Buy
3,247,463
+27,892
+0.9% +$69K 0.03% 736
2025
Q1 		$4.41M Sell
3,219,571
-59,625
-2% -$146K 0.01% 1306
2024
Q4 		$10.1M Buy
3,279,196
+592,000
+22% +$2.75M 0.02% 956
2024
Q3 		$20.7M Buy
2,687,196
+2,410,187
+870% +$23M 0.03% 612
2024
Q2 		$2.38M Buy
+277,009
New +$2.14M ﹤0.01% 1468
2023
Q4 		– Sell
-844,377
Closed -$9.51M – 2906
2023
Q3 		$9.51M Buy
+844,377
New +$5.15M 0.02% 862
2022
Q2 		– Sell
-31,781
Closed -$241K – 3185
2022
Q1 		$241K Buy
+31,781
New +$275K ﹤0.01% 1981

Other funds holding TNGX

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Balyasny Asset Management's TNGX Position: Q2 2026 in Review

Balyasny Asset Management reduced its Tango Therapeutics (TNGX) stake by 47% in Q2 2026, selling an estimated $44.8M and leaving 2,016,379 shares worth $63M. The position accounts for 0.08% of the portfolio, ranked #299.

Balyasny Asset Management first reported a position in TNGX in Q1 2022 and has held it in 11 quarters since. The position peaked at $80.1M in Q1 2026. 248 funds tracked by Wall St. Rank hold TNGX as of Q2 2026.

  • Balyasny Asset Management held 2,016,379 shares of Tango Therapeutics worth $63M as of Q2 2026.
  • Balyasny Asset Management sold 1,810,280 Tango Therapeutics shares in Q2 2026, an estimated $44.8M.
  • Tango Therapeutics made up 0.08% of Balyasny Asset Management's portfolio in Q2 2026, its #299 holding.
  • Balyasny Asset Management first reported a position in Tango Therapeutics in Q1 2022 and has held it in 11 quarters since.
  • Balyasny Asset Management's Tango Therapeutics position peaked at $80.1M in Q1 2026.
  • 248 funds tracked by Wall St. Rank held Tango Therapeutics as of Q2 2026.

Based on Balyasny Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.